Zai Lab Ltd

ZLAB.US
Healthcare · Biotechnology
18.62
-0.02 (-0.11%)
USD · NASDAQ

Company Information

Company Name
Zai Lab Ltd
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US98887Q1040
CIK: 0001704292
CUSIP: 98887Q104
Currency: USD
Full Time Employees: 1,784
Phone: 86 21 6163 2588
Fiscal Year End: December
IPO Date: Sep 20, 2017
Description:

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.

Address:

Building B, Pudong, China, 201203

People

Directors & Officers

Name Title Year Born
Dr. Ying Du Ph.D. Founder, Chairperson & CEO 1966
Dr. Rafael G. Amado M.D. President and Head of Global Research & Development 1964
Dr. Yajing Chen Ph.D. Chief Financial Officer 1968
Mr. Frazor Titus Edmondson III, J.D. Chief Legal Officer & Corporate Secretary 1966
Ms. Christine Chiou Senior VP & Head of Investor Relations NA
Dr. James Yan DABT, M.D., Ph.D. Chief Operating Officer of Global R&D 1964
Dr. Shan He Ph.D. Senior VP & Chief Business Officer NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Apr 06, 2026 Rafael Amado N/A Sale 2.74K $20.45 $56.01K
Apr 06, 2026 Yajing Chen N/A Sale 853.00 $20.45 $17.44K
Apr 06, 2026 Ying Du N/A Sale 2.65K $20.45 $54.25K
Apr 06, 2026 Joshua L Smiley N/A Sale 3.02K $20.45 $61.70K
Apr 02, 2026 Joshua L Smiley N/A Sale 9.61K $20.39 $196.03K
Apr 02, 2026 Rafael Amado N/A Sale 9.91K $20.39 $202.06K
Apr 02, 2026 Yajing Chen N/A Sale 5.20K $20.39 $106.01K
Apr 02, 2026 Ying Du N/A Sale 5.58K $20.39 $113.69K
Mar 17, 2026 Richard Gaynor N/A Purchase 1.73K $18.91 $32.73K
Mar 13, 2026 Joshua L Smiley N/A Sale 1.97K $18.63 $36.63K
Mar 13, 2026 Rafael Amado N/A Sale 2.96K $18.63 $55.09K
Mar 13, 2026 Yajing Chen N/A Sale 1.70K $18.63 $31.73K
Dec 31, 2025 Rafael Amado N/A Sale 10.79K $17.43 $188.02K
Nov 03, 2025 Yajing Chen N/A Sale 240.00 $26.83 $6.44K
Sep 10, 2025 Joshua L Smiley N/A Purchase 10.00K $28.91 $289.10K
Aug 18, 2025 Joshua L Smiley N/A Sale 6.64K $36.24 $240.67K
Aug 15, 2025 Yajing Chen N/A Sale 1.44K $35.42 $50.93K
Aug 13, 2025 Ying Du N/A Sale 46.39K $35.47 $1.65M
Aug 11, 2025 Ying Du N/A Sale 50.00K $34.64 $1.73M
Aug 08, 2025 Rafael Amado N/A Sale 3.00K $35.00 $105.00K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
RTW INVESTMENTS, LLC 6.57M Mar 31, 2026 5.82% $1.23 -5.53%
RA Capital Management, LLC 5.71M Mar 31, 2026 5.05% $1.14 0.00%
Frazier Life Sciences Management, L.P. 1.90M Mar 31, 2026 1.68% $0.92 0.00%
Citadel Advisors Llc 1.69M Mar 31, 2026 1.50% $0.01 0.05%
BAMCO Inc 1.66M Mar 31, 2026 1.47% $0.09 16.95%
ADAR1 Capital Management LLC 1.43M Mar 31, 2026 1.26% $1.58 14.35%
FMR Inc 1.26M Mar 31, 2026 1.12% $0.00 -12.36%
BlackRock Inc 865.15K Mar 31, 2026 0.77% $0.00 36.20%
Rock Springs Capital Management LP 814.71K Mar 31, 2026 0.72% $0.90 0.39%
CAM Group Holding A/S 510.00K Mar 31, 2026 0.45% $0.21 0.00%
UBS Group AG 504.19K Mar 31, 2026 0.45% $0.00 -71.71%
B Group, Inc 450.65K Mar 31, 2026 0.40% $6.28 12.66%
Schroder Investment Management Group 393.17K Mar 31, 2026 0.35% $0.01 31.12%
NAN FUNG TRINITY (HK) Ltd 346.47K Mar 31, 2026 0.31% $0.72 28.33%
Two Sigma Investments LLC 309.72K Mar 31, 2026 0.27% $0.00 949.09%
T. Rowe Price Associates, Inc. 291.64K Mar 31, 2026 0.26% $0.00 -51.63%
SUPERSTRING CAPITAL MANAGEMENT LP 275.82K Mar 31, 2026 0.24% $3.71 40.11%
Jane Street Group LLC 267.93K Mar 31, 2026 0.24% $0.00 -29.87%
Ameriprise Financial Inc 243.56K Mar 31, 2026 0.22% $0.00 34.46%
Aberdeen Group PLC 237.74K Mar 31, 2026 0.21% $0.01 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Baron Emerging Markets Institutional 1.37M 1.21% ▼ 1.90% Jun 30, 2026
2 Baron Emerging Markets Strategy 1.37M 1.21% ▼ 1.90% Jun 30, 2026
3 Strategic Advisers Fidelity Em Mkts 738.51K 0.65% ▼ 32.28% May 31, 2026
4 iShares Biotechnology ETF 640.16K 0.57% ▲ 1.05% Jun 30, 2026
5 Fidelity Series Emerging Markets 600.58K 0.53% ▼ 32.86% May 31, 2026
6 Fidelity Growth Compy Commingled Pl S 518.68K 0.46% ▲ 0.08% May 31, 2026
7 C WorldWide Healthcare Select 1A 510.00K 0.45% ▲ 0.00% Jun 30, 2026
8 International Biotechnology Ord 393.17K 0.35% ▲ 0.00% Mar 31, 2026
9 Fidelity Growth Company Fund 332.19K 0.29% ▲ 0.00% May 31, 2026
10 FIAM Select Emerging Markets Eq CIT Cl C 297.16K 0.26% ▼ 36.38% May 31, 2026

Financial Highlights

Market Cap: $2.10B
EBITDA: $-227.01M
Book Value: $5.96
Earnings/Share: $-1.70
Profit Margin: -39.29%
Operating Margin: -69.66%
ROA (TTM): -13.36%
ROE (TTM): -24.19%
Revenue (TTM): $453.28M
Revenue/Share (TTM): $4.11
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -6.50%

Valuation Metrics

Enterprise Value: $1.79B
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 112.92M
Shares Float: 91.71M
% Insiders: 215.80%
% Institutions: 3,125.00%
Short % Float: 5.74%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$460.16M
Cost of Goods Sold
adjust
$-191.08M
Gross Profit
subtotal
$269.08M
SG&A
adjust
$-277.61M
R&D
adjust
$-220.90M
Operating Income
subtotal
$-223.57M
Other / Non-Operating Items
adjust
$48.04M
Net Income
subtotal
$-175.54M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about ZLAB.US!